Table 2.
The role of SLC7A11 inhibition in reduced resistance to anticancer treatment
| Mechanism | Cancer type | Treatment |
|---|---|---|
| ROS decrease, GSH increase | BRAFV600E mutant melanoma | Vorinostat [30] |
| CDDP-resistant hepatocellular carcinoma | Combination of CDDP and sulfasalazine [139] | |
| CDDP-resistant lung cancer | Combination of CDDP and salazosulfapyridine [143] | |
| CDDP-resistant head and neck cancer | Combination of cisplatin, aspirin and sorafenib [144] | |
| CDDP-resistant bladder cancer | Combination of CDDP and sulfasalazine [94] | |
| 5-fluorouracil-resistant gastric cancer | Combination of 5-fluorouracil and sulfasalazine [145] | |
| Celastrol-resistant glioma | Combination of celastrol and sulfasalazine [146] | |
| Cannabidiol-resistant gliblastoma | Combination of cannabidiol and sulfasalazine [147] | |
| Tumor cells resistant to cold plasma | Combination of sulfasalazine and cold plasma [61] | |
| Doxorubicin-resistant breast cancer stem cells | Combination of anti-xCT vaccination and doxorubicin [23] | |
| Ferroptosis | CDDP-resistant head and neck cancer | Combination of CDDP and sulfasalazine [62] |